Skip to main content

Maravai Lifesciences Holdings, Inc Investor Event Transcript, Nov 12, 2026

Maravai Lifesciences Holdings, Inc. (MRVI)

Marvai Life Sciences expects TriLink to drive long-term growth, with just over 50 GMP customers and mRNA programs projected at $5 to $50 million per year at peak; management targets a 35% EBITDA margin as revenues scale. AI summary

Investor Event Transcript 2026-11-12 For: 2026-12-31
Added on November 12, 2026

Conference Transcript - MRVI 2026-11-12

Dan, Analyst — Stifel

Okay, welcome back to the 2026 Stifel Healthcare Conference. Back on the life sciences side, happy to have Maravai with us today. We have Raj Ashropoda, CFO, and Jimmy Burnworth, VP of Finance and Sales Operations. Guys, thanks very much for spending some time with us here today.

Raj Asarpota, CFO

Thank you, Dan. Appreciate it. I'm going to go through a few slides here, and then we can pick it up with Q&A. We'll be presenting forward-looking statements, so keep that in mind. And to kick it off, you know, Marvai Life Sciences is a leading provider of critical technologies and products that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics with a particular focus on... Both nucleic acid production and biosafety testing through our two marquee franchises or brand names, Trilink and Cygnus. So Trilink is our diversified genetic medicine platform with three distinct sub-segments. You have mRNA with CleanCap and ModTail as the two franchise products with robust R&D and clinical pipeline. Our CDMO service that provides support from discovery to late-stage clinical development, and then specialty chemistry, which consists of oligonucleotide synthesis, oligos, NTPs, and consumables. On the Cygnus side, we have a comprehensive portfolio of host cell protein assays, including mass spectrometry and broad-based assays, along with contract services, mock V clearance kits, and custom assays. Just to point out here, Cygnus HCP kits are used in 31 of 31 commercialized CAR-T cell and gene therapies. So a little bit more of a deeper dive into our two reporting segments, Cygnus and Trilink, both that are very different growth dynamics. Starting with Trilink, like I mentioned, that's our genetic medicine platform accounting for 65% of revenues. And within Trilink, the three buckets, again, as I mentioned. Previously, mRNA consists of discovery. That's both research and preclinical, GMP, and then commercial. As a percent of revenue, that represents 35%, and the five-year expected growth rate there is in the high single digits and low double digits when you fold in commercial revenues expected in 28 and 29. CDMO is our contract manufacturing, representing under 10% of revenue and growing at low double digits. And then specialty chemistry, that's oligosynthesis reagents and consumables, is a little bit over 20%, growing at low single digits. So TriLink, again, is the flagship that will carry the long-term high-growth opportunity for the company, especially as commercial revenue starts to flow in. And then Cygnus represents 35% of our revenue growing at mid-single digits and is the gold standard, steady-eddy, high-margin cash flow business. Looking at TriLink across every stage of mRNA drug development, you know, Notwithstanding the spies like us story in the headlines today, we still think NVIDIA is a good analog, and the analogy we like to draw is just as NVIDIA does not build AI models but supplies the compute that every model runs on. Similarly, Marvai does not develop the drug, but we supply differentiated technologies and services that hundreds of mRNA and genetic medicine programs are built on. So walking from left to right here, as we think about the stages of drug development, on the basic research side, we supply. Clean cap, mottail, NTPs, oligos, enzymes. And this is where we seed the market and spur the start of new programs where pricing is not as critical. We want as many programs here to be seeded as possible. And then once you move into preclinical, you get a little bit of a scale up there. Again, clean cap, mottail, and GNP enzyme adoption happens here. And then as you move into clinical. That's where you get a significant step up in both volume and price as each phase advances. It's critical to point out here that our target for this year was to get 50, you know, to onboard 10 new GMP customers, which we exceeded, and we're now at just over 50 GMP customers. And then once you get to the commercial stage, you're now significantly scaling clean cap, and you're also getting the GMP opportunity with Mottail and GMP enzymes, and we think this is a $5 to a $50 million per program opportunity per year at peak, and I'll provide a little bit more detail on that. So, as we think about clinical phase advancement, again, as each phase advances, it increases our potential revenue per program. As you look at this visual here, the revenue per program, when you are in the preclinical stage, it's pretty low, and we think the estimated chances of a program reaching commercialization when it's preclinical are fairly low. But then as you progress into phase one, 10% of those programs have a chance to make You know, get to commercial on market. Phase one and phase one to two is about 12% probability. Phase two is 15. And then once the program's in phase three, there's a 58 to 60% chance that it hits the market. So we probably wait all of that to help us frame the opportunity for commercial revenue. So we look at five different modalities here, and the... The formula here is you look at each of these modalities, the number of patients per year that would be enrolled in a program, the number of doses that would be administered, the mRNA per dose, and then the price realization impact per unit to assign a value to each of these programs. So as you'd expect, a prophylactic vaccine, high patient enrollment similar to a COVID vaccine with low doses per year. Also, the mRNA per dose is low, and because of batch pricing, the value that we assign to such a program is on the low side. As you step up to personalized medicine and cancer vaccines, the patient's per year is lower than a prophylactic vaccine, but the number of doses are significantly higher, and the mRNA per dose, given that there are multiple doses, represents a medium opportunity based on the price and premium we can command there. Likewise, for an mRNA therapeutic, the doses per year now are pretty high, and the mRNA per dose is even higher than a cancer vaccine, and then the price per unit is the highest in terms of opportunity for the company. Likewise, in in vivo gene editing, high patients enrolled, the mRNA dose is pretty high. And again, we've got opportunity to realize price, giving it a high value. And then ex vivo cell therapy is about a medium based on the number of patients that would be enrolled. So estimated commercial peak by modality, again, 5 million on the low side for something like a prophylactic vaccine and up to 50 million plus per program for the rest of the modalities. And as we think about the pipeline in terms of where our pipeline is in terms of phase and modality, the current program mix is 40% in phase one, 40% in phase one and two, and phase two or phase three is about 20%. And then as you look to the right, like I mentioned, 50 GMP customers in 26, average of two to three programs per GMP customer, so that gives you a little bit of context on the shots at goal we have and the diversity of programs. And then majority of our pipeline is for the higher-value modalities, so 75% plus is in those categories outside of prophylactic vaccines. I'll just close it out by, you know, talking a little bit about programs that are in the clinic today. They, of course, use CleanCap, but programs that enter the clinic now, they also leverage both our Motel and GMP enzymes, which gives us even more opportunity to carry those GMP products and, therefore, realize into higher revenue streams. So, with that, Dan.

Dan, Analyst — Stifel

Yeah, that's a nice breakdown. I think people have been finding the way in which you've been describing the makeup of the businesses to be super helpful, just in terms of trying to understand what has been and what might be going forward. So thank you for those. Maybe just as an overall statement, Raj, to start, 2026 has been a more consistent year for Marivai. Can you just talk about where you think you are with visibility across the industry and in those areas, you know, probably speaking that we just highlighted there?

Raj Asarpota, CFO

Sure. I think, you know, I'll comment on the business overall, but then specifically by certain segments. But our visibility now compared to what it was 18 months ago has gotten significantly better. I think the COVID bleed down is kind of behind us. It's, you know, as you strip. That noise out, the visibility that we have now, you know, with our, both our. GMP customers and on the discovery side is a lot better as programs have continued to advance and our forecasting capability has gotten better. So on the discovery side, we have, you know, within quarter, we have enough line of sight based on run rate business, forecasts that are available to the commercial team based on their engagement and dialogue with customers. Likewise, for Cygnus, it's pretty good. And then the lumpy part, obviously, with GMP, we have a really good line of sight into the funnel, and based on customer schedules, we're able to make those calls either falling within the quarter or depending on what those commitments are in terms of contractual agreements, maybe a little bit longer, which creates that lumpiness, if you will.

Dan, Analyst — Stifel

Yeah, okay, so GMP is a lumpy business, but the visibility when you compare it to just, you know, prior periods where you were trying to figure out how much coping material you needed is better than that, I would assume.

Raj Asarpota, CFO

Definitely, especially as you think about the programs that are advancing the number of, you know, our GMP customer base is fairly small. You know, like I said, we have 50 customers, so we understand them really well, understand what their schedules look like, and you can't obviously time everything, but generally, it's pretty good visibility. Okay.

Dan, Analyst — Stifel

All right. Let me just go into mRNA a little bit. Just under half of TriLink, I believe, and in the quarter, in 3Q, GMP within that was up 30, and then Drug Discovery was up 27 percent, so. Nice growth in both pieces of that. Drug discovery, you increase the number of customers by 70 in the quarter, which strikes me as a pretty high number for a 90-day period. Where are these folks coming from? And then can you just talk to the amount of sort of new activity that's driving those guys through the door versus something that's just different about your capabilities? And reaching them maybe with, you know, a commercial force that you didn't have or wasn't as effective.

Raj Asarpota, CFO

I think I'll start with the capabilities. So, you know, I think the Marwai used to be known as a clean cap company. But I think now that's changed with the breadth of the portfolio that we're offering. So when you think about Motel that's bringing customers in, we have... IVT kits, we have enzymes, we've got the mRNA builder. So all those factors, along with the sales engagement and the capability that we've built, is starting to pan out, pay out, you know, like it's playing out to be attracting new customers in. So that 27% growth is not just a function of, you know, market growth, but more of us taking share. And that's kind of how it's been playing out. In terms of, Jimmy, any comments on the program advancement?

Jimmy Burnworth, Other

Yeah, I'd just say we did a deep dive on the 70 new customers, and it really did drive the acceleration, especially in that basic research world. But when you look at it, it's really three things. It's new products. It's customers coming to us because of our channel, our web, e-commerce, and AI capabilities. I'd say drove over half of those new customer acquisitions. And as Raj mentioned, because of the better segmentation that we've done with the sales force, our sales team is doing a better job at onboarding those larger customers.

Dan, Analyst — Stifel

Okay. And does that tend to be pretty sticky? I mean, do you get some one and dones in there as they're just sort of trialing? Or when you get them in the door as a drug discovery customer, do you feel pretty good about, you know, obviously there's a probability waiting to all of this throughout the continuum, but do you feel good about them sticking with you?

Jimmy Burnworth, Other

Yeah, we definitely do. It's a long tail of customers, but we certainly have those that proceed.

Dan, Analyst — Stifel

Okay.

Raj Asarpota, CFO

Yeah, keep in mind, I mean, that whole discovery business was declining like 20% last year. And we've seen, you know, through the year, I think Q1 was like 7%, went to like 15, 20%. And then finally in Q3, it was up to 27. Yeah.

Dan, Analyst — Stifel

Is there anything about, I mean, was the number, was that like 70 as a sustainable number? How does that strike you as an idea? I mean, was it? Just an exceptional quarter, and so 4Q is a...

Raj Asarpota, CFO

Well, Q2 was a record, too. We saw like 67 customers going to 70% plus. Now, I don't know if it's going to sustain at that level, but certainly in terms of getting new customers in, we feel pretty good about that.

Dan, Analyst — Stifel

Yeah, so the traction as far as bringing new business in at the earlier stages is good. And then naturally you have... Those folks graduating, hopefully, through the process, the clinical development process. And we've talked about the size of a preclinical order being 100K. I don't know whether that's representative of the overall mix right now. Would you say that that's true? But I'd like to just sort of ask a question. About the scale-up that you referenced in there, because obviously the amount of material that you use goes up throughout the process. Right.

Jimmy Burnworth, Other

Yeah, I think the way to think about it, at the very early stage, it's tens of thousands of dollars as you're starting a program, and then as you get deeper into preclinical, then you get into those six-figure. And then once you reach the clinic, that's where you really see a volume scale up, and it can be, you know, four or five times, you know, that preclinical number.

Dan, Analyst — Stifel

Okay, so I've got a $10,000 customer, shows up for the first time, $5,000 to $10,000, sees some success, and that becomes a $100,000 preclinical program. The multipliers feel like they should, I mean, you know, is a four to five times increase for phase one, is that a reasonable assumption?

Jimmy Burnworth, Other

Yeah, that's the right way to think about it.

Dan, Analyst — Stifel

And then, you know, obviously it doesn't jump that much for the next set of phases, but still multiples of what we're talking about, so maybe two to three times.

Jimmy Burnworth, Other

Yeah, for sure.

Dan, Analyst — Stifel

So you could have a $100,000 program right before the clinical process starts, and by the time you're done, that's a two to three million dollar.

Raj Asarpota, CFO

Yeah, which is what gives that variability once you're into GMP, right? So you have these large orders with schedules that are driven by customer program timing, but yes, I mean, that's definitely.

Jimmy Burnworth, Other

The other dynamic that we see happening is more and more programs are moving away from infectious disease, where the mix is overall improving to cancer vaccines, mRNA therapeutics, in vivo gene editing. Those are programs that require significantly more product and reagent than infectious disease, and it can be in the magnitude of 20 times, 100 times more mRNA. Yeah.

Dan, Analyst — Stifel

So can we talk about that a little bit? I mean, the personalized vaccines story got a boost in the middle of the year. Obviously, Merck-Moderna was sort of a proof of principle there. How much more material would you say a project like that would require versus a vaccine? And then if you look at some of the other types of programs that you've talked about, protein replacement, et cetera, same question there. And then what would be the mix there? I mean, I think you had a slide there, but you kind of.

Raj Asarpota, CFO

Yeah, I mean, I think, yeah, let's, so like a vaccine, let's say it's like 50. Um, micrograms per dose. If you're thinking about a vaccine, that's, that's at least one milligram and with at least nine doses administered, you can do the math on how much that of a multiplier that is. And likewise, for a therapeutic, um, that's like 35.

Jimmy Burnworth, Other

Yeah. I mean, it's even, you know, 15, 20 times more than a, than a cancer vaccine. Okay.

Raj Asarpota, CFO

Those are significantly higher in terms of dosage.

Dan, Analyst — Stifel

Are you, how are you situated with the personal vaccine developers? I mean, you had a program that you talked about. I think the first time that I remember you talking about it was at the NLS Day in 2023. It was an unnamed partner. Is that partnership still going on? And then, you know, would you say that if we think back to the summer and the Merck-Moderna news, will you, will you be? Should we be looking for some of your partners?

Raj Asarpota, CFO

Yeah, the answer is yes. We are still working with our partner. The answer is yes on things that are in the pipeline. We obviously can comment on customers, but the answer is yes.

Dan, Analyst — Stifel

Okay, so I've got the scale up in the clinical development process. I've got material per dose going up. And that seems like for pretty much everything on the non-vaccine side, there's a multiplier there. Yep. And then I've got just this idea that within the programs, you've got multiple shots on goal. So I guess the question becomes, do your customers on the GMP side usually start with one program and then move to two or three? Or when you get that business, is it typically across the board?

Jimmy Burnworth, Other

It depends on the customer. On average, I would say it usually starts with one and scales up, but with the larger customers, they certainly have even more than three programs going on at a time.

Dan, Analyst — Stifel

Okay, so if I'm rolling this up right, you've got your early stage funnel that, you know, is expanding in terms of application and the number of programs, increases on the GMP side naturally as some of those graduate. Within that group, you have the material going up and the trial size, you know, just being a greater number of individuals in it. And then you also have new products in the mix that I assume are... From a technology's point of view, advantageous. And then also, is there a pricing element to some of that as well?

Raj Asarpota, CFO

Yeah, I mean, if you think about Mottail, that's, you know, when we launched that about a year ago, started out with 70 customers, went to 125 the following quarter, now we're north of 180. Yeah. And when you did the great thing about how we're taking that to market is combining that with clean cap and that bundling opportunity. One gives us stickiness and is like a 95% attachment, but also mottails at a premium. So we get that. Price pop. And then once that moves into GMP, obviously, same thing happens based on what we just went through in terms of modality analysis. It gives you a significant pricing premium.

Dan, Analyst — Stifel

What about price as the size of the program grows and presumably the discount on the material? Is that an offset? That's, you know, because obviously, my point is, like, there's things like,

Raj Asarpota, CFO

yeah, of course, I mean, that elasticity is situational. And as things start to scale, you would expect to see a little bit of negotiating, but that's just, you know, when it comes to that.

Jimmy Burnworth, Other

Yeah, we want to make all programs economically viable, so we'll certainly work with customers, but I think even as we move into the other modalities, there's opportunity to get a higher price than in a prophylactic vaccine because you're now ordering in small batches and more custom order batches versus a large, one-time, once-a-year order.

Dan, Analyst — Stifel

I would imagine the discounting that went on. During the COVID vaccine period is about as extreme as you would guess. Exactly. How about the competitive environment? Is there anything that's changed there either favorably or just in a way that makes you think that the operating environment is more difficult in one corner of the market than another?

Raj Asarpota, CFO

I, I mean, just based on our execution and growth, we are seeing I mean, it's starting to get a little stable now in terms of funding and in our execution. You know, I don't know if anyone that has mottail right now and clean caps certainly through COVID has been established as a gold standard. Of course, you have enzymatic capping. But I think even as you step away from that, the more and more we start getting into design services through mRNA and building better mRNA constructs for customers, providing bespoke approaches to developing more targeted. You know, experiments for our customers. I think all of that improves the competitive advantage that we have.

Dan, Analyst — Stifel

Okay. And then can you just maybe touch on from a commercial standpoint, and maybe this brings Cygnus into the conversation too, just the way that you're going about. Reaching customers from an e-commerce standpoint, and then just being efficient with how it is that you touch some of these new customers that I imagine are, you know, you know of them in the industry, but they're coming to you for the first time in a lot of ways, too. So how is the commercial organization evolving in order to sort of? Fit the fact that the market is more than just COVID vaccines these days.

Raj Asarpota, CFO

Yeah.

Jimmy Burnworth, Other

Jimmy's doing that every day. I think the segmentation work that we did a year ago is now really paying off in that the long tail of customers placing small orders are getting great service through our e-commerce platform and our AI mRNA builder. We've seen significant adoption in that, and like I said, it was one of the leading drivers of new customer acquisition. So because that is now supporting this tail, it's given our sales reps a lot more time to sell more than just a product, but also to sell a whole platform of products across MRNA. And so they're upselling ModTail. They're working with them to make sure that they're designing a better MRNA construct. They're also supporting just overall service capabilities and making sure that it's a great experience to work with us. Okay.

Raj Asarpota, CFO

And then, you know, I think just one last point there, too, given the use of AI across the company, we're getting. Just so much more better than our sales operations capability, giving them the account planning and tools so that they are even more focused as they approach and engage with these customers.

Dan, Analyst — Stifel

Okay. Yeah. Maybe to that point, I mean, operationally, gross margins, when I'm thinking about the way that the P&L evolves, that's one thing. But gross margins have also changed quite a bit over the last 12 months. I think you had $65 million of cost restructuring last year. How does that situate you for 2027 when you think about how it is that gross margin? I mean, we're never going back to COVID gross margin. I think we would all agree that that's not happening. But it does feel like there's still an upward trajectory here, particularly given the volume. So, you know, how would you have us think about where gross margin?

Raj Asarpota, CFO

Yeah, no, that's exactly it. You know, we've talked a lot about the cost base being reset, such that now every dollar of revenue. More than 70% kind of falls to the bottom line. So that holds true. And literally, we can flow in hundreds of millions of dollars without meaningfully changing our operating structure. So I think in terms of gross margin, a lot of that benefit that we did from the restructuring last year, we saw 1,600 basis points of improvement year over year. And EBITDA has grown like 70 million year-over-year, and cash flow is generating nicely. So I think going forward, it's a function of obviously the mix of product. So you've got very high margins in GMP and discovery, and it's a little bit offset by CDMO, but that's a small part of the business, but continuing to get better. So it's a little bit of a functional product mix and then continuing to get manufacturing efficiencies that will drive gross margin.

Dan, Analyst — Stifel

Is there still room to go on manufacturing efficiency?

Raj Asarpota, CFO

I think so, a little bit.

Dan, Analyst — Stifel

I think so.

Jimmy Burnworth, Other

The biggest initiative this year is really rolling out AI operationally across the board. And so over 40% of our employees are now weekly active users. We've collected hundreds of use cases and are really doing everything we can to drive adoption there, and we're seeing, you know, results from that, and we think that in the future it'll mean, you know, fewer incremental headcount needed, and as people leave, you know, a little less backfilling.

Raj Asarpota, CFO

We already see that in terms of when people leave, there's backfills that are not needed. Okay, that's good.

Jimmy Burnworth, Other

I think that's happening a lot of different places.

Dan, Analyst — Stifel

Okay. Just maybe a short-term question on gross margins in 4Q. Why the step down? I mean, you've been pretty substantially above where the 4Q implied gross margin number is. Is there something discreet there that you're kind of thinking about?

Jimmy Burnworth, Other

I mean, I think this is not – I think we said it on the call. We are being fairly conservative on the Q4. And we want to leave some level of discretion to make sure that we account for mix and other potential risks. But we feel very confident in meeting those.

Dan, Analyst — Stifel

Okay. Maybe just to move it down the P&L, the EBITDA line. What do you think the chances are that you can return to something like 35% or 40% EBITDA margins? I mean, those were at one time, you know, ex-COVID, even before COVID, that was a level that was attainable through a certain level of volume. You sound encouraged by what you're seeing on volume. So, you know, maybe just talk to me about whether that's a realistic goal or not.

Raj Asarpota, CFO

Yeah, that is personally my objective is I'd love to get back to that 35% range. And that's really going to be a function of our execution on the commercial front, right? So as those commercial revenues start to fold in, as we continue to build a robust product pipeline, we continue to leverage price. Given, again, like the cost structure that's already set, there's no reason why we couldn't get there.

Dan, Analyst — Stifel

Maybe just the last question, thinking about the portfolio. M&A, is that something that you see as interesting from here? I mean, are you continuing to look to build out the offerings, or is it kind of about what you have today and pushing that as hard as you can?

Raj Asarpota, CFO

Yeah, I would say the priority is to continue with the organic initiatives and growth that we have. Having said that, should there be an opportunity in something that's not dilutive to the business and something that's not? Just technology versus an actual product or service will be opportunistic about that. But really, it's about organic growth at this point. Okay. Yeah.

Dan, Analyst — Stifel

Okay, gentlemen, I appreciate you spending some time. I know you guys are moving around quite a bit like everyone else. So thanks. Thanks for participating.

Raj Asarpota, CFO

Thank you, Dan. Appreciate it.